| 77.75 -4.73 (-5.73%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 121.46 | 1-year : | 144.53 |
| Resists | First : | 103.99 | Second : | 123.75 |
| Pivot price | 86.06 |
|||
| Supports | First : | 72.03 | Second : | 59.93 |
| MAs | MA(5) : | 82.32 |
MA(20) : | 86.68 |
| MA(100) : | 68.1  |
MA(250) : | 47.35 |
|
| MACD | MACD : | 0.2 |
Signal : | 1.8 |
| %K %D | K(14,3) : | 8.8 |
D(3) : | 11.8 |
| RSI | RSI(14): 42.7 |
|||
| 52-week | High : | 123.75 | Low : | 23.17 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ DRUG ] has closed below the lower bollinger band by 6.9%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 22.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 82.73 - 83.19 | 83.19 - 83.56 |
| Low: | 76.07 - 76.7 | 76.7 - 77.21 |
| Close: | 76.83 - 77.76 | 77.76 - 78.51 |
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Sat, 31 Jan 2026
Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Rises By 67.5% - MarketBeat
Fri, 30 Jan 2026
Several Bright Minds Biosciences Insiders Sell Shares Sending Potential Negative Signal - simplywall.st
Mon, 12 Jan 2026
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Fri, 09 Jan 2026
Bright Minds Biosciences closes $175 million public offering - Investing.com
Thu, 08 Jan 2026
Bright Minds Biosciences (NASDAQ: DRUG) launches $175M equity raise for trials - Stock Titan
Wed, 07 Jan 2026
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 11.4 (%) |
| Held by Institutions | 63.4 (%) |
| Shares Short | 337 (K) |
| Shares Short P.Month | 271 (K) |
| EPS | -1.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.73 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.8 % |
| Return on Equity (ttm) | -28 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -60.75 |
| PEG Ratio | 0 |
| Price to Book value | 10.04 |
| Price to Sales | 0 |
| Price to Cash Flow | -87.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|